# A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

> **NCT00780039** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 58 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00780039
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10-01
- **Primary completion:** 2007-09-06
- **Final completion:** 2007-09-06
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780039, "A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00780039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*